Chengtian Technology Secures Nearly RMB 100 Million Series B Funding to Accelerate Global Expansion of Embodied Intelligent Exoskeletons

Hangzhou RoboCT Technology Development Co., Ltd. (hereinafter referred to as “RoboCT”) recently announced the completion of its Series B financing round, raising nearly RMB 100 million. The round was led by Wuxi Capital Group, with HAOYUE CAPITAL serving as the exclusive financial advisor. The funds will be primarily allocated to the research, development, and iteration of embodied intelligent exoskeleton technologies; the R&D and regulatory registration of new brain-computer interface products; the expansion of production facilities; and global market expansion. These efforts aim to further promote the practical application of embodied intelligent exoskeleton wearable robots in rehabilitation, elderly care, and consumer markets, accelerate the expansion of domestic and international distribution networks, and establish RoboCT as a globally leading exoskeleton technology enterprise.

Confronted with the dual challenges of “supply-demand imbalance” and “technical barriers” in China’s rehabilitation market, RoboCT has introduced innovative solutions through the deep integration of embodied intelligent exoskeleton robot technology and large AI models. Its independently developed rehabilitation exoskeleton robots and solutions leverage multimodal biosignal fusion algorithms—integrating electromyography (EMG), electroencephalography (EEG), spinal cord signals, and motion posture data—to generate dynamic rehabilitation pathways for users, advancing exoskeleton technology toward higher-dimensional precision applications. With an intention recognition accuracy rate of 98.7%, the system not only triples daily service efficiency but also improves gait training efficiency for stroke patients by approximately 53%.

Currently, RoboCT has established a comprehensive portfolio of medical-grade products covering neurological rehabilitation, musculoskeletal rehabilitation, and mobility compensation. The company has served over 623,000 users, with the total walking distance achieved by its users equivalent to circling the Earth twice. Its new generation of rehabilitative exoskeletons, featuring brain-computer interfaces, spinal cord stimulation, and "brain-spine integration" technologies, has been deployed in collaboration with top-tier institutions such as Xuanwu Hospital of Capital Medical University and Huashan Hospital of Fudan University. Multiple successful cases of combined "spinal cord stimulation + exoskeleton" therapy have been reported. In one notable case, a patient who had been unable to walk for a year following a car accident underwent surgery; the patient achieved independent standing within 14 days post-operation and completed five meters of independent walking within 28 days. Expanded trials are now underway across China, with successful implementations recorded in more than 14 cities, ranging from Hainan in the south, to Xinjiang in the west, and Heilongjiang in the north. This marks another significant step forward for RoboCT in advancing human-machine integration, positioning exoskeleton robots as new human organs and contributing to the evolution of humanity.

RoboCT’s founding and R&D teams have dedicated over a decade to the field of exoskeleton robotics. Leveraging “in-house technology development + cost restructuring” as their core competitive advantage, they have successfully achieved 100% localization of key components, reduced module costs to one-tenth of the industry average, and attained gross margins for complete units that are more than twice the industry mean. As a key supplier of hardware core components for embodied AI technologies, RoboCT has served various robotics technology companies across 40 countries and regions worldwide. More importantly, RoboCT is breaking the traditional perception of exoskeletons as merely “medical devices,” accelerating its penetration into consumer markets and global application scenarios, thereby reinforcing its central position in providing hardware solutions for the field of embodied AI.

RoboCT’s New Series Drives Iteration of Exoskeleton Robots, Extending Applications from Medical Rehabilitation to Home, Community, and Outdoor LeisureLaunched in 2025, RoboCT’s EasyGo powered exoskeleton robot series targets consumer scenarios such as mobility assistance for the elderly and outdoor sports. Featuring lightweight carbon fiber materials and bionic structures, the device provides walking assistance without requiring a power source, with a price point of approximately RMB 2,500. As thousand-yuan-level exoskeletons enter households, they will effectively propel the evolution of embodied intelligent exoskeleton robots from “medical devices” to “extensions of human physical capabilities,” redefining human-machine interaction concepts while unlocking broader commercial potential.

In 2023, the “14th Five-Year Plan for the Development of the Robotics Industry” explicitly listed rehabilitation robots as a key focus area. Eleven provinces and municipalities, including Beijing, Jiangsu, and Hebei, have incorporated exoskeleton therapy into their medical insurance coverage, reducing patients’ out-of-pocket costs by more than 60%. Meanwhile, the convergence of the “silver economy” and the “Robotics+” policy has propelled the industry into a period of explosive growth. The market size for rehabilitation robots in China is projected to exceed RMB 20 billion by 2025, with a compound annual growth rate (CAGR) of 47.3%.

The Chinese government’s support for the health and wellness industry has accelerated the development of exoskeleton technology. With dual backing from policy and capital, RoboCT is continuously expanding its global footprint. The company’s flagship UGO series of rehabilitation exoskeletons obtained EU CE certification in late 2024, facilitating faster market entry into Southeast Asia, the Middle East, Australia, and Europe, and marking a new stage in the globalization of its rehabilitation exoskeleton products. Meanwhile, the GoGo powered assistive exoskeleton robot, part of the active series and scheduled for launch in the second half of 2025, will be made available to consumers through overseas crowdfunding, further promoting the effective global coverage of embodied AI products. Additionally, the implementation of new manufacturing facilities funded by this latest financing round will effectively ensure the production and global supply of exoskeleton robots.

Against the backdrop of accelerating global aging and an explosive surge in demand for health and elderly care, embodied intelligent wearable exoskeleton robot technology is rapidly transitioning from “science fiction fantasy” to “accessible reality.” In this process, the founding team’s original aspiration resonates with the power of capital: technological breakthroughs require the persistence of long-termists, while industrial transformation relies on the foresight of strategic investors. Dr. Wang Tian, founder of RoboCT, believes, “Technology should serve everyone, especially those unable to live independently due to physical limitations. Robotics is inherently designed to make life easier, more dignified, and more respectable. This philosophy drives our continuous exploration and innovation in the field of exoskeleton robots. Exoskeleton robots are not merely products for rehabilitation and elderly care; they constitute a distinct category of robotics. You will see RoboCT’s exoskeleton robots increasingly applied in fields such as entertainment, industry, safety, and transportation.”

The investment decisions by prominent investors such as Wuxi Capital Group underscore the capital market’s strong confidence in the “hard tech + big health” sector. Amidst the blue ocean of the trillion-dollar silver economy, RoboCT is leveraging technology inclusivity and global expansion to reshape the value of life with technological warmth, while advancing the scenario-based application of embodied intelligence technologies.

Wuxi Capital Group: “RoboCT is one of the few companies that possess both technological depth and commercialization capabilities. Its capacity for mass production in China, global strategy, and precise grasp of policy trends have shown us the leapfrog potential of exoskeleton technology from ‘addressing pain points’ to ‘creating value.’ We are optimistic about its dual potential in the rehabilitation and elderly care sector as well as the consumer market, and look forward to seeing it lead Chinese technology onto the global stage.”

Wuxi Capital Group is a state-owned venture capital firm integrating seed, angel, venture, equity, M&A, and S fund investments. The company has established a fund system covering the entire corporate lifecycle, with total assets under management exceeding RMB 260 billion, providing comprehensive support tailored to enterprises at different development stages. Focusing on strategic emerging industries such as biomedicine, integrated circuits, dual-carbon energy conservation, and advanced manufacturing, it has cumulatively invested in over 1,600 companies through its managed funds and participated in nurturing more than 110 listed enterprises, including Longda Shares, NCE Power, Angelalign, and Zhongjie Precision Industry.

RoboCT, founded in 2017, has built its core competitive barriers through "independent R&D and cost restructuring." By deeply integrating cutting-edge technologies such as embodied intelligence, artificial intelligence, data analytics, and cloud computing, the company develops intelligent products and personalized solutions. RoboCT aims to enhance human physical capabilities through robotics, expand the application of exoskeleton technology across industries including industrial manufacturing, healthcare, safety, transportation, and entertainment, and ultimately realize the vision of "Human Plus," ensuring that everyone can benefit from robotic services.